Investigating how angiogenin and plexin-B2 contribute to treatment resistance in glioblastoma
Angiogenin and plexin-B2 in therapeutic resistance and disease relapse of GBM
This study is looking at glioblastoma, a tough type of brain cancer, to find out how certain stubborn cells contribute to its return after treatment, and it aims to discover new ways to target these cells to help improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11047317 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain cancer known for its poor prognosis and tendency to recur after treatment. The study aims to understand the role of glioma stem cells, which are resistant to conventional therapies, in the recurrence of this disease. By examining the interactions between angiogenin and its receptor plexin-B2, the researchers hope to identify new therapeutic targets that could help eliminate these resistant cells. The approach includes using monoclonal antibodies to inhibit plexin-B2, potentially improving treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma, particularly those experiencing tumor recurrence after standard treatments.
Not a fit: Patients with glioblastoma who are not eligible for experimental therapies or those with early-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively target and reduce glioma stem cells, potentially improving survival rates for glioblastoma patients.
How similar studies have performed: Previous research has shown promise in targeting glioma stem cells and their pathways, suggesting that this approach could lead to significant advancements in glioblastoma treatment.
Where this research is happening
Boston, United States
- Tufts Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Hu, Guo-Fu — Tufts Medical Center
- Study coordinator: Hu, Guo-Fu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.